Childhood obesity is common and consequential. About 20% of children in the U.S. have obesity, and the downstream effects include early-onset chronic diseases that can progress to organ failure in young adulthood. The author, a transplant surgeon who also trains and practices in obesity medicine, describes seeing adults in their 30s and 40s whose organ failure traces back to childhood obesity and notes that obesity can itself be a barrier to transplant.
The piece cites published evidence that adolescents with severe obesity are up to nine times more likely to develop chronic kidney disease in young adulthood, even in the absence of diabetes or hypertension. Childhood fatty liver disease is associated with a dramatically increased mortality risk — described in source data as about 40-fold — and has become a rapidly growing indication for liver transplantation among young adults.
The author and his research team analyzed prescription trends and reported a 310-fold increase in GLP-1 receptor agonist prescriptions for children aged 8–11 with obesity since 2019. Despite this steep relative rise, absolute use remains limited: among more than 3.5 million children ages 8–11 with obesity in the study population, only 0.6% received a GLP-1 prescription.
These findings highlight two coexisting realities: rapid expansion of prescription rates in recent years, and continued underuse relative to the population affected by obesity and its complications.
According to the study, physicians are largely reserving GLP-1s for children with the most severe disease. The source reports that 94% of children prescribed GLP-1s had severe obesity. Many of these children already demonstrate adult-type comorbidities, including sleep apnea, prediabetes, hypertension, metabolic dysfunction–associated steatotic liver disease (formerly called fatty liver disease), and hyperlipidemia.
This pattern suggests clinicians are targeting medications to patients with demonstrable, obesity-related medical complications rather than prescribing broadly across the spectrum of elevated weight.
At the time of the source article, several GLP-1 receptor agonists are approved for use in adolescents aged 12 and older for obesity, but none were approved for younger children. The author notes that FDA approval for younger age groups could expand insurance coverage and reduce disparities in access observed in the study.
However, the author also cautions that expanding approvals could lead to wider use in less severe cases, a shift that is not justified without long-term data on effects of these medications on growth and puberty. The source emphasizes that such data gaps remain an important limitation and rationale for cautious clinical use in younger children.
The author frames pediatric obesity as largely produced by environmental and systemic factors: neighborhoods that discourage physical activity, food environments dominated by ultra-processed foods marketed directly to children, and family-level pressures including rising costs, food insecurity, and limited time for healthy meal preparation.
He argues that blame should not be placed on individual families; rather, policy and structural solutions are needed. The source references three policy interventions — taxing sugar-sweetened beverages, ending tax deductions for advertising unhealthy food to children, and improving school nutrition standards — that have been projected in cited analyses to produce net savings in health care costs greater than their implementation costs.
The author rejects a dichotomy between system-level prevention and clinical treatment. He describes this contrast as a false binary that can lead to therapeutic nihilism. Instead, he argues both approaches are necessary and complementary: pursue policies that reduce population-level incidence while offering evidence-based medical treatment to children who already have obesity and its complications.
Clinically, withholding treatment from children with severe obesity and medical complications risks allowing disease progression that will result in more medicalization and worse outcomes in adulthood. In that sense, prescribing GLP-1s for appropriate, high-risk pediatric patients is portrayed as responding to existing medical harm rather than initiating medicalization.
Transplantation is lifesaving but comes with substantial burdens: long wait times, lifelong immunosuppression, and the risk of rejection. The author contends that intervening earlier in the course of pediatric obesity could prevent some instances of irreversible organ damage and reduce future need for transplantation. His clinical motivation for pursuing obesity medicine training was to move upstream of end-stage disease and to meet patients earlier in their disease trajectories.
The source concludes that treating children who have already been harmed by obesity and changing the systems that produced obesity are not competing priorities; both are required to improve long-term outcomes and keep more young adults off transplant waiting lists.